Head-To-Head Analysis: Decision Diagnostics (OTCMKTS:DECN) vs. Strata Skin Sciences (NASDAQ:SSKN)

Strata Skin Sciences (NASDAQ:SSKN) and Decision Diagnostics (OTCMKTS:DECN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Strata Skin Sciences and Decision Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Skin Sciences	$32.85 million	0.22	-$10.09 million	($2.67)	-0.52
Decision Diagnostics	N/A	N/A	N/A	N/A	N/A

Decision Diagnostics has lower revenue, but higher earnings than Strata Skin Sciences.

Risk & Volatility

Strata Skin Sciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Decision Diagnostics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500.

Insider and Institutional Ownership

32.4% of Strata Skin Sciences shares are owned by institutional investors. 40.9% of Strata Skin Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Strata Skin Sciences and Decision Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Strata Skin Sciences	-35.13%	-266.94%	-32.66%
Decision Diagnostics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations for Strata Skin Sciences and Decision Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Skin Sciences	1	0	1	0	2.00
Decision Diagnostics	0	0	0	0	0.00

Strata Skin Sciences presently has a consensus price target of $6.00, indicating a potential upside of 334.78%. Given Strata Skin Sciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Strata Skin Sciences is more favorable than Decision Diagnostics.

Summary

Strata Skin Sciences beats Decision Diagnostics on 7 of the 10 factors compared between the two stocks.

About Strata Skin Sciences

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.

About Decision Diagnostics

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.